Advertisement
News
Advertisement

ArQule partner halts lung cancer drug trial

Thu, 08/30/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

Woburn-based biotech company ArQule Inc. has learned that partner Kyowa Hakko Kirin Co., Ltd., which has exclusive development rights to ArQule’s lead product candidate tivantinib in Japan, has suspended patient enrollment in its ongoing Phase 3 trial dubbed ATTENTION.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading